Last reviewed · How we verify
HB-1
At a glance
| Generic name | HB-1 |
|---|---|
| Also known as | Fixed dose Telmisartan / Verapamil tablet |
| Sponsor | Honeybrains Biotech LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of HB-1 for Panic Disorder (PHASE2)
- CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (PHASE2)
- Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A
- Cell Salvage During Caesarean Section (CSCS) (NA)
- Safety and Efficacy of HB-1 for Panic Disorder (PHASE2)
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (PHASE1)
- A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB-1 CI brief — competitive landscape report
- HB-1 updates RSS · CI watch RSS
- Honeybrains Biotech LLC portfolio CI